nach oben

Supportive Care in Cancer

Erschienen in:

23.01.2020 | Original Article

EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy

verfasst von: Ting-Yu Chiang, Hung-Chih Hsu, Sui-Whi Jane, Shu-Ching Chen

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purposes of this study were to assess the levels of symptom distress, body image, and epidermal growth factor receptor inhibitors (EGFRI)-associated health-related quality of life (QoL); identify the factors related to EGFRI-associated health-related QoL; and examine the differences in EGFRI-associated health-related QoL by grade of skin toxicity in mCRC patients receiving target therapy.

Methods

This cross-sectional study examined mCRC patients who received cetuximab-based target therapy from the oncology and CRC inpatient and outpatient departments of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ symptom distress, body image, and EGFRI-associated health-related QoL.

Results

Of the 111 mCRC patients studied, 79.2% reported acneiform eruption and 52.2% reported paronychia. The most common symptoms were dry skin and itching. Poor EGFRI-associated health-related QoL was associated with more symptom distress, more negative body image, a higher cumulative dose of target therapy, and being married; these factors explained 66.6% of the variance in EGFRI-associated health-related QoL.

Conclusion

Patient-specific skin care and emotional support are needed to relieve distressful dermatological symptoms and emotional distress during and post-treatment for mCRC.

International agency for research on cancer (2019) Cancer fact sheets: colorectal cancer. Available from: https://gco.iarc.fr/today/fact-sheets-cancers? cancer=6&type=0&sex=0. Ministry of Health Welfare, Taiwan, ROC. 2017 statistics cause of death. Available from: http://www.doh.gov.tw. Accessed May 16, 2019

Taiwan cancer registry (2019) 2018 Annual Report. Available from: http://crs.cph.ntu.edu.tw/. Accessed May 16, 2019

Berretta M, Alessandrini L, De Divitiis C et al (2017) Serum and tissue markers in colorectal cancer: state of art. Crit Rev Oncol Hematol 111:103–116. https://doi.org/10.1016/j.critrevonc.2017.01.007CrossRefPubMed

Stulhofer Buzina D, Martinac I, Ledic Drvar D et al (2016) Adverse reaction to cetuximab, an epidermal growth factor receptor inhibitor. Acta Dermatovenerol Croati 24:70–72

Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169–1176CrossRef

D'Alessio A, Cecchini S, Di Mauro D et al (2016) Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Tumori 102. https://doi.org/10.5301/tj.5000579

Folprecht G, Lutz MP, Schoffski P et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450–456. https://doi.org/10.1093/annonc/mdj084CrossRefPubMed

Giuliani J, Marzola M (2013) Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor? J Gastrointest Cancer 44:241–345. https://doi.org/10.1007/s12029-013-9485-7CrossRefPubMed

Takada S, Sagawa T, Fujikawa K, Tahatsu K, Fukai Y, Hashishita H, Takahashi Y, Endo M (2018) Skin disorders and primary tumor location as prognostic factors in patients with metastatic colorectal cancer treated with cetuximab and chemotherapy. Asian Pac J Cancer Prev 19:2325–2330. https://doi.org/10.22034/APJCP.2018.19.8.2325CrossRefPubMedPubMedCentral

10.

Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C, Cui H (2019) Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Biosci Trends 12:537–552. https://doi.org/10.5582/bst.2018.01246CrossRefPubMed

11.

Charalambous A, Charalambous M (2016) “I lost my image, the image others know me by”: findings from a hermeneutic phenomenological study of patients living with treatment-induced cutaneous toxicities. Res Nurs Health 39:187–196. https://doi.org/10.1002/nur.21722CrossRefPubMed

12.

Charles C, Razavi D, Bungener C, Mateus C, Lanoy E, Verschoore M, Dauchy S, Robert C (2016) Impact of skin toxicities associated with targeted cancer therapies on body image: a prospective study. Clin Drug Investig 36:235–242. https://doi.org/10.1007/s40261-015-0373-8CrossRefPubMed

13.

De Tursi M, Zilli M, Carella C et al (2017) Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. OncoTargets Ther 16:3007–3015. https://doi.org/10.2147/OTT.S127795 eCollection 2017CrossRef

14.

Boone SL, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152–159CrossRef

15.

Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic. Cancer 1:634–656CrossRef

16.

National comprehensive cancer network (2018) NCCN guidelines for patients: colon cancers 2018. Available From: http://www.nccn.org. Accessed May 16, 2019

17.

McCorkle R, Young K (1978) Development of symptom distress scale. Cancer Nurs 1:373–378CrossRef

18.

Veale D, Eshkevari E, Kanakam N, Ellison N, Costa A, Werner T (2014) The appearance anxiety inventory: validation of a process measure in the treatment of body dysmorphic disorder. Behav Cogn Psychother 42:605–616. https://doi.org/10.1017/S1352465813000556CrossRefPubMed

19.

Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME (2013) The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer 21:1033–1041. https://doi.org/10.1007/s00520-012-1623-4CrossRefPubMed

20.

National cancer institute (2010) Common terminology criteria for adverse events (CTCAE), Version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed May 16, 2019

21.

Bonomo P, Loi M, Desideri I et al (2017) Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: a systematic review. Crit Rev Oncol Hematol 120:98–110. https://doi.org/10.1016/j.critrevonc.2017.10.011CrossRefPubMed

22.

Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351–1357. https://doi.org/10.1200/JCO.2008.21.7828CrossRefPubMed

23.

Lacouture ME, Maitland ML, Segaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 8:509–522. https://doi.org/10.1007/s00520-009-0744-xCrossRef

24.

Fitzpatrick TB (1975) Sun and skin. Journal de Médecine Esthétique [in French] 2:33–34

25.

Australian Radiation Protection and Nuclear Safety Agency (2007) Fitzpatrick skin phenotype. Available from: https://www.arpansa.gov.au/sites/default/files/legacy/pubs/RadiationProtection/FitzpatrickSkinType.pdf. Accessed May 16, 2019

26.

Chan MWM, Shek SY, Yeung CK, Chan HH (2019) A prospective study in the treatment of lentigines in Asian skin using 532 nm picosecond Nd:YAG laser. Lasers Surg Med 51:767–773CrossRef

27.

Jo HC, Kim DY (2019) Correlation between light absorbance and skin color using fabricated skin phantoms with different colors. Lasers Med Sci 1–8. https://doi.org/10.1007/s10103-019-02888-0

28.

Chang YL, Huang BS, Hung TM, Lin CY, Chen SC (2019) Factors influencing body image in posttreatment oral cavity cancer patients. Psychooncology 28:1127–1133. https://doi.org/10.1002/pon.5067CrossRefPubMed

29.

Chen SC, Huang BS, Hung TM et al (2019) Impact of a behavior change program and health education on social interactions in survivors of head and neck cancer: randomized controlled trial. Psychooncology 28:293–300. https://doi.org/10.1002/pon.4939CrossRefPubMed

30.

Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Baños A, Köhne CH (2012) Skin toxicity and quality of life in patients with metastatic cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 12:438. https://doi.org/10.1186/1471-2407-12-438CrossRefPubMedPubMedCentral

31.

Dahlhoff M, Frances D, Kloepper JE, Paus R, Schäfer M, Niemann C, Schneider MR (2014) Overexpression of epigen during embryonic development induces reversible, epidermal growth factor receptor-dependent sebaceous gland hyperplasia. Mol Cell Biol 34:3086–3095. https://doi.org/10.1128/MCB.00302-14CrossRefPubMedPubMedCentral

32.

Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803–812CrossRef

33.

Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H (2007) Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43:845–851CrossRef

34.

Esser P, Mehnert A, Johansen C, Hornemann B, Dietz A, Ernst J (2018) Body image mediates the effect of cancer-related stigmatization on depression: a new target for intervention. Psychooncology 27:193–198. https://doi.org/10.1002/pon.4494CrossRefPubMed

35.

Phelan SM, Griffin JM, Jackson GL, Zafar SY, Hellerstedt W, Stahre M, Nelson D, Zullig LL, Burgess DJ, van Ryn M (2013) Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer. Psychooncology 22:65–73. https://doi.org/10.1002/pon.2048CrossRefPubMed

36.

Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14:327–333. https://doi.org/10.1007/s40257-013-0021-0CrossRefPubMed

37.

Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116:3916–3923. https://doi.org/10.1002/cncr.25090CrossRefPubMed

38.

Stanculeanu DL, Zob D, Toma OC, Georgescu B, Papagheorghe L, Mihaila RI (2017) Cutaneous toxicities of molecular targeted therapies. Maedica (Buchar) 12:48–54

39.

Lee JJ, Kroshinsky D, Hoang MP (2017) Cutaneous reactions to targeted therapy. Am J Dermatopathol 39:67–82. https://doi.org/10.1097/DAD.0000000000000504CrossRefPubMed

40.

Davidson A, Williams J (2019) Factors affecting quality of life in patients experiencing facial disfigurement due to surgery for head and neck cancer. Br J Nurs 28:180–184. https://doi.org/10.12968/bjon.2019.28.3.180CrossRefPubMed

41.

Hirpara DH, Azin A, Mulcahy V et al (2019) The impact of surgical modality on self-reported body image, quality of life and survivorship after anterior resection for colorectal cancer–a mixed methods study. Can J Surg 62:1–8. https://doi.org/10.1503/cjs.014717CrossRef

42.

Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven K, Kaptein AA (2016) Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer 24:513–521. https://doi.org/10.1007/s00520-015-2781-yCrossRefPubMed

43.

Bensadoun RJ, Humbert P, Krutman J, Luger T, Triller R, Rougier A, Seite S, Dreno B (2013) Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Cancer Manag Res 5:401–408. https://doi.org/10.2147/CMAR.S52256 eCollection 2013CrossRefPubMedPubMedCentral

Titel: EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy
verfasst von: Ting-Yu Chiang
Hung-Chih Hsu
Sui-Whi Jane
Shu-Ching Chen
Publikationsdatum: 23.01.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 10/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05321-3

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Patients’ satisfaction with a supportive care program for young breast cancer patients in Mexico: Joven & Fuerte supports patients’ needs and eases their illness process

A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer

Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin

COVID-19 und Krebs: Empfehlungen zur Reduktion der antiemetischen Prophylaxe

An exploratory study in breast cancer of factors involved in the use and communication with health professionals of Internet information

Nutrition interventions to improve the appetite of adults undergoing cancer treatment: a systematic review

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie